Pretreatment PET/CT Standardized Uptake Values Play a Role in Predicting Response to Treatment and Survival in Patients with Small Cell Lung Cancer

被引:7
作者
Dinc, Nur Sener [1 ]
Aydin, Kubra [2 ]
Odabas, Hatice [1 ]
Ercelep, Ozlem [1 ]
Tufan, Gulnihal [3 ]
Seker, Mesut [4 ]
Yasar, Nurgul [1 ]
Aydin, Dincer [1 ]
Yuksel, Sinemis [1 ]
Mert, Aslihan [1 ]
Ozcelik, Melike [1 ]
Korkmaz, Taner [5 ]
Yildiz, Ramazan [3 ]
Aliustaoglu, Mehmet [1 ]
Mayadagli, Alpaslan [4 ]
Dane, Faysal [5 ]
Gumus, Mahmut [4 ]
机构
[1] Kartal Dr Lutfi Kirdar Training & Res Hosp, Semsi Denizer Cad E-5 Karayolu Ceyali Mevkii, TR-34890 Istanbul, Turkey
[2] Ankara Oncol Training & Res Hosp, Ankara, Turkey
[3] Gazi Univ, Ankara, Turkey
[4] Bezmialem Vakif Univ, Istanbul, Turkey
[5] Marmara Univ Hosp, Istanbul, Turkey
关键词
Small cell lung cancer; PET/CT; SUV; MANAGEMENT;
D O I
10.1159/000444272
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: We investigated the role of standardized uptake values (SUVs) of the primary tumor in small cell lung cancer (SCLC) patients. Patients and Methods: The relationship between SUV and response to treatment was investigated using receiver operating characteristic (ROC) curve analysis, and the efficient cut-off value for detecting response to treatment was determined. The effects of SUV on response to treatment and survival were investigated. Results: 90 patients with a median age of 58 years (range 39-83 years) were included. Median follow-up was 11 months. The suitable cut-off SUV for determination of response was found to be 10 in ROC analysis. The sensitivity and specificity of this value were 85.7% (95% confidence interval (95% CI) 63-96) and 61.8% (95% CI 49-73) (area under the curve 0.783; p = 0.0001), respectively. The overall objective response rate in patients with involvement above the cut-off value was 93.3% compared to 59.1% in those with involvement below the cut-off value (p < 0.0001). In uni- and multivariate analysis, favorable effects of limited-stage disease on response to treatment were established (p < 0.05). The effect of an SUV higher than the cut-off value on progression-free survival was borderline (p = 0.085). Conclusion: These data may contribute to identifying prognostic disease characteristics and response to treatment. (C) 2016 S. Karger GmbH, Freiburg
引用
收藏
页码:130 / 134
页数:5
相关论文
共 18 条
[1]   Evaluation of outcome prediction and disease extension by quantitative 2-deoxy-2-[18F] fluoro-d-glucose with positron emission tomography in patients with small cell lung cancer [J].
Arslan, Nuri ;
Tuncel, Murat ;
Kuzhan, Okan ;
Alagoz, Engin ;
Budakoglu, Burcin ;
Ozet, Ahmet ;
Ozguven, Mehmet Ali .
ANNALS OF NUCLEAR MEDICINE, 2011, 25 (06) :406-413
[2]   Impact of positron emission tomography on the management of patients with small-cell lung cancer - Preliminary experience [J].
Blum, R ;
MacManus, MP ;
Rischin, D ;
Michael, M ;
Ball, D ;
Hicks, RJ .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (02) :164-171
[3]   The future in diagnosis and staging of lung cancer: Positron emission tomography [J].
Fischer, Barbara M. ;
Mortensen, Jann .
RESPIRATION, 2006, 73 (03) :267-276
[4]   High Tumor Metabolic Activity as Measured by Fluorodeoxyglucose Positron Emission Tomography Is Associated with Poor Prognosis in Limited and Extensive Stage Small-Cell Lung Cancer [J].
Lee, Young Joo ;
Cho, Arthur ;
Cho, Byoung Chul ;
Yun, Mijin ;
Kim, Se Kyu ;
Chang, Joon ;
Moon, Jin Wook ;
Park, In Kyu ;
Choi, Hye Jin ;
Kim, Joo-Hang .
CLINICAL CANCER RESEARCH, 2009, 15 (07) :2426-2432
[5]   Staging small cell lung cancer: Veterans administration lung study group versus international association for the study of lung cancer-what limits limited disease? [J].
Micke, P ;
Faldum, A ;
Metz, T ;
Beeh, KM ;
Bittinger, F ;
Hengstler, JG ;
Buhl, R .
LUNG CANCER, 2002, 37 (03) :271-276
[6]   Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer [J].
Oh, Jong-Ryool ;
Seo, Ji-Hyoung ;
Chong, Ari ;
Min, Jung-Joon ;
Song, Ho-Chun ;
Kim, Young-Chul ;
Bom, Hee-Seung .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 (06) :925-935
[7]  
Ohri N, 2015, JNCI-J NATL CANCER I, V16, P4107
[8]  
Paesmans M, 2000, CANCER-AM CANCER SOC, V89, P523, DOI 10.1002/1097-0142(20000801)89:3<523::AID-CNCR7>3.0.CO
[9]  
2-6
[10]   Prognostic value of [18F]FDG-PET imaging in small cell lung cancer [J].
Pandit, N ;
Gonen, M ;
Krug, L ;
Larson, SM .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (01) :78-84